{
    "2021-03-30": [
        [
            {
                "time": "",
                "original_text": "H P V 疫苗国产背后的生意经：“一针难求”待解 有公司毛利90％",
                "features": {
                    "keywords": [
                        "HPV疫苗",
                        "国产",
                        "生意经",
                        "一针难求",
                        "高毛利"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药周报：关注细分领域里质地优良、估值相对合理具有安全边际、增长确定性强的标的",
                "features": {
                    "keywords": [
                        "医药",
                        "周报",
                        "细分领域",
                        "质地优良",
                        "估值合理",
                        "安全边际",
                        "增长确定性"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "中国银河 - 万泰生物：IVD+疫苗双轮驱动，业绩高速增长【公司研究】",
                "features": {
                    "keywords": [
                        "中国银河",
                        "万泰生物",
                        "IVD",
                        "疫苗",
                        "双轮驱动",
                        "业绩高速增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}